Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | FLT1 | P17948 | 4/20 | 0.52 |
| ▸ | TEK | Q02763 | 4/20 | 0.52 |
| ▸ | NSD3 | Q9BZ95 | 1/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NSD2 | O96028 | 1/20 | 0.38 |
| ▸ | LDLR | P01130 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.36 |
| ▸ | HPGDS | O60760 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15013190 | 0.83 | PTGS2 (0.42) | KDRFLT1TEKNSD3NTRK1 | |
| SCHEMBL12457300 | 0.78 | NSD2 (0.40) | KDRFLT1TEKNSD3LMNA | |
| SCHEMBL461609 | 0.74 | PDE10A (0.45) | LMNAALDH1A1KDM4EGAAHPGD | |
| SCHEMBL4767226 | 0.74 | KDR (0.59) | KDRFLT1TEKNSD3NTRK1 | |
| SCHEMBL4767231 | 0.74 | KDR (0.59) | KDRFLT1TEKNSD3NTRK1 | |
| SCHEMBL4774618 | 0.73 | TEK (0.56) | KDRFLT1TEKLMNATSHR | |
| SCHEMBL1009513 | 0.73 | NSD3 (0.83) | KDRFLT1TEKNSD3LMNA | |
| SCHEMBL19159715 | 0.73 | NSD3 (0.56) | KDRFLT1TEKNSD3NTRK1 | |
| SCHEMBL4774516 | 0.72 | TEK (0.67) | KDRFLT1TEKNSD3 | |
| SCHEMBL4774512 | 0.72 | TEK (0.67) | KDRFLT1TEKNSD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114634665-B | Vinyl polymer/modified polyhydroxy polymer composites and uses thereof | 国家电投集团氢能科技发展有限公司 | 2024-10-22 | — | — | CN | disclosed |
| CN-114634665-A | Vinyl polymer/modified polyhydroxy polymer composites and uses thereof | 国家电投集团氢能科技发展有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1575963-B1 | ANTI-ANGIOGENETIC THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2008-05-07 | — | — | EP | disclosed |
| EP-1537112-B1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2006-04-19 | — | — | EP | disclosed |
| US-20060069109-A1 | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | US | disclosed |
| CN-1751052-A | Therapeutic agents | ASTRAZENECA AB (SE) | 2006-03-22 | — | — | CN | disclosed |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| CN-1688579-A | Condensed pyridines and pyrimidines with TIE2 (TEK) activity | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1575963-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1537112-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | Astrazeneca AB (SE) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004058776-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004013141-A1 | CONDENSED PYRIDINES AND PYRIMIDINES WITH TIE2 (TEK) ACTIVITY | ASTRAZENECA AB (SE) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069109-A1 | Therapeutic agents | TIE1, TEK, KDR | KDR 3/4885FLT1 4/4885TEK 2/4885 |
| US-20050256140-A1 | Condensed pyridines and pyrimidines with tie2 (tek) activity | TIE1, TEK, KDR | KDR 3/4885FLT1 6/4885TEK 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.